Macular Degeneration News and Research RSS Feed - Macular Degeneration News and Research

Macular degeneration is a disease associated with aging that gradually destroys sharp, central vision. Central vision is needed for seeing objects clearly and for common daily tasks such as reading and driving.
Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures. [More]

Medicare doctor payment data reveals much about health system

The trove of data has the potential to reveal faults in drug pricing, potential fraud and could help regulators and consumers track medical spending -- but could take years to sort out. [More]
Analysis of Medicare pay shows variations in drugs used and earnings by specialists

Analysis of Medicare pay shows variations in drugs used and earnings by specialists

The Washington Post examines how drugs administered by doctors is different in various regions of the country. Other outlets look at other issues, including how eye doctors are among the highest paid specialty. [More]
Taking a close-to-home look at the Medicare billing data

Taking a close-to-home look at the Medicare billing data

Other news outlets offer localized takes on the Medicare data, including the Miami Herald's coverage of a physician who emerged as the federal program's top-paid doctor, the Philadelphia Inquirer's look at an ambulance business' billing patterns and the Seattle Times' examination of ophthalmologists. [More]

First Edition: April 10, 2014

Today's headlines include a range of stories taking additional looks at the Medicare physician payment data released yesterday by the Centers for Medicare & Medicaid Services. [More]
Researchers receive President of Ireland Young Researcher Award from Science Foundation Ireland

Researchers receive President of Ireland Young Researcher Award from Science Foundation Ireland

President of Ireland, Michael D. Higgins, has today received three recipients of the Science Foundation Ireland, President of Ireland Young Researcher Award (PIYRA) at áras an Uachtaráin. [More]

BIDMC scientist wins Gairdner Award for landmark discovery in the field of angiogenesis

Harold F. Dvorak, MD, senior investigator in the Center for Vascular Biology Research at Beth Israel Deaconess Medical Center and former chairman of BIDMC's Department of Pathology, is one of eight scientists to win the 2014 Canada Gairdner Awards, which recognize some of the most significant medical discoveries from around the world. Awarded by the Gairdner Foundation, based in Canada, the awards are considered among the most prestigious international awards in medical research. [More]

Study: Daily dietary supplements not associated with reduced risk for CVD in elderly

Daily dietary supplements of omega-3 polyunsaturated fatty acids (also found in fish) or lutein and zeaxanthin (nutrients found in green leafy vegetables) were not associated with reduced risk for cardiovascular disease (CVD) in elderly patients with the eye disease age-related macular degeneration. [More]
Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs. [More]
Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. [More]

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD). [More]
Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Bayer Yakuhin submits marketing authorization application in Japan for EYLEA Injection

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application for marketing authorization for EYLEA (aflibercept) Injection for the treatment of patients with diabetic macular edema (DME) to the Japanese Ministry of Health, Labour and Welfare. [More]
Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein. [More]

Ophthotech reports net loss of $20.4 million for fourth quarter 2013

Ophthotech Corporation today announced financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on the Company's business and product development programs. [More]

Regeneron receives FDA acceptance for EYLEA injection for treatment of macular edema

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company's supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Macular Edema following Branch Retinal Vein Occlusion (BRVO). [More]
Study reveals that color vision abnormalities increase with age

Study reveals that color vision abnormalities increase with age

​Abnormal color vision increases significantly with aging-affecting one-half or more of people in the oldest age groups, reports a study in Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
Study indicates relationship between multivitamin supplement use and cataract risk in men

Study indicates relationship between multivitamin supplement use and cataract risk in men

Long-term daily multivitamin supplement use may lower cataract risk in men, according to a study of nearly 15,000 male physicians published this month in Ophthalmology, the journal of the American Academy of Ophthalmology [More]

Newly developed compound may allow blind see light

Progressive degeneration of photoreceptors-the rods and cones of the eyes-causes blinding diseases such as retinitis pigmentosa and age-related macular degeneration. While there are currently no available treatments to reverse this degeneration, a newly developed compound allows other cells in the eye to act like photoreceptors. As described in a study appearing in the February 19 issue of the Cell Press journal Neuron, the compound may be a potential drug candidate for treating patients suffering from degenerative retinal disorders. [More]

Perceptual learning can improve vision and on field performance in baseball

With a little practice on a computer or iPad-25 minutes a day, 4 days a week, for 2 months-our brains can learn to see better, according to a study of University of California, Riverside baseball players reported in the Cell Press journal Current Biology on February 17. [More]
Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

Pitt’s CMI funds 6 research groups for Early Stage Medical Technology Research and Development

The University of Pittsburgh's Center for Medical Innovation (CMI) awarded a total of $82,000 to six research groups through its 2013 Round-2 Pilot Funding Program for Early Stage Medical Technology Research and Development. [More]